サマリー

米国のポリメラーゼ連鎖反応市場は、2022年の44億6,581万米ドルから2030年には111億6,847万米ドルに達し、2023年から2030年の予測期間中に年平均成長率12.2％で成長すると予測されている。

市場細分化：
製品タイプ別（試薬、機器、消耗品、ソフトウェア、サービス）、手法別（リアルタイムPCR、リバース・トランスクリプターゼ（RT）PCR、コンベンショナルPCR、マルチプレックスPCR、ネステッドPCR、ホットスタートPCR、ロングレンジPCR、アセンブリーPCR、インバースPCR、その他）、用途別（臨床、ライフサイエンスおよび関連研究、法医学、環境微生物学、その他）、エンドユーザー（製薬・バイオテクノロジー企業、病院・診療所、診断研究所、学術・研究機関、法医学研究所、リファレンス研究所、その他）、流通チャネル（直接入札、小売販売、その他）、国（米国） - 産業トレンド米国） - 2030年までの産業動向と予測

米国のポリメラーゼ連鎖反応市場ダイナミクスの概要

ドライバー

- PCR診断薬の利用可能性の上昇

抑制要因

- 新しい複雑な装置の解析の制限
機会

- 研究開発活動の活発化

市場プレイヤー

米国のポリメラーゼ連鎖反応市場に参入している主な企業は以下の通りである：
- ベックマン・コールター社
- ホフマン・ラ・ロシュ社
- プロメガ社
- イルミナ社
- バイオ・ラッド・ラボラトリーズ社
- QIAGEN
- メルク KGaA
- ジェンスクリプト
- サーモフィッシャーサイエンティフィック
- パーキンエルマー社
- エンゾライフサイエンス社
- バイオメリュー
- タカラバイオ株式会社
- LGCバイオサーチテクノロジーズ
- メリディアンバイオサイエンス株式会社
- ルミネックス株式会社
- アジレント・テクノロジー株式会社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF THE U.S. POLYMERASE CHAIN REACTION MARKET 13
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 CURRENCY AND PRICING 19
2.5 DBMR TRIPOD DATA VALIDATION MODEL 20
2.6 MULTIVARIATE MODELLING 23
2.7 PRODUCT TYPE LIFELINE CURVE 23
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.9 DBMR MARKET POSITION GRID 25
2.10 MARKET END USER COVERAGE GRID 26
2.11 VENDOR SHARE ANALYSIS 27
2.12 SECONDARY SOURCES 28
2.13 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 31
4.1 PESTLE ANALYSIS 32
4.2 PORTER'S FIVE FORCES MODEL 33
4.3 INSTALLATION BASE 34
4.4 COST ANALYSIS 38
4.5 VALUE CHAIN ANALYSIS 39
4.6 HEALTHCARE ECONOMY 40
4.6.1 HEALTHCARE EXPENDITURE 40
4.6.2 CAPITAL EXPENDITURE 40
4.6.3 CAPEX TRENDS 41
4.6.4 CAPEX ALLOCATIONS 41
4.6.5 FUNDING SOURCES 42
4.6.6 INDUSTRY BENCHMARKS 42
4.6.7 GDP RATIO IN OVERALL GDP 43
4.6.8 HEALTHCARE SYSTEM STRUCTURE 43
4.6.9 GOVERNMENT POLICIES 44
4.6.10 ECONOMIC DEVELOPMENT 45
4.7 INDUSTRY INSIGHTS 46
4.7.1 MICRO AND MACROECONOMIC FACTORS 46
4.7.2 PENETRATION AND GROWTH PROSPECT MAPPING 47
4.7.3 KEY PRICING STRATEGIES 47
4.8 TECHNOLOGY ROADMAP 48
5 REGULATORY COMPLIANCE 49
5.1 REGULATORY AUTHORITIES 49
5.2 REGULATORY CLASSIFICATIONS 49
5.3 REGULATORY SUBMISSIONS 50
5.4 INTERNATIONAL HARMONIZATION 51
5.5 COMPLIANCE AND QUALITY MANAGEMENT SCENARIO 51
5.6 REGULATORY CHALLENGES AND STRATEGY 52
6 MARKET OVERVIEW, U.S. POLYMERASE CHAIN REACTION MARKET 53
6.1 DRIVERS 55
6.1.1 RISE IN THE AVAILABILITY OF PCR DIAGNOSTICS 55
6.1.2 INCREASING APPLICATION OF PCR 55
6.1.3 INCREASING DEMAND FOR PERSONALIZED MEDICINE 56
6.2 RESTRAINTS 56
6.2.1 LIMITATIONS WHILE ANALYZING THE NOVEL COMPLEX DEVICE 56
6.2.2 LONG APPROVAL PROCEDURE 57
6.3 OPPORTUNITIES 57
6.3.1 GOVERNMENT INITIATIVES TO IMPLEMENT SCREENING PROGRAMS FOR VARIOUS DISEASES 57
6.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 58
6.4 CHALLENGES 58
6.4.1 INCREASE IN THE PRODUCT RECALLS 58
6.4.2 HIGH COST OF PCR MEDICAL DEVICE DEVELOPMENT 59 
7 U.S. POLYMERASE CHAIN REACTION MARKET, BY PRODUCT TYPE 60
7.1 OVERVIEW 61
7.2 REAGENTS 64
7.2.1 DNA OR PCR TEMPLATES 65
7.2.2 DNA POLYMERASE I ENZYME 65
7.2.2.1 TAQ DNA POLYMERASE 65
7.2.2.2 HIGH-FIDELITY DNA POLYMERASE 65
7.2.2.3 GREEN TAQ DNA POLYMERASE 65
7.2.2.4 HOT START TAQ DNA POLYMERASE 66
7.2.2.5 PROOFREADING DNA POLYMERASE 66
7.2.2.6 OTHERS 66
7.2.3 PRIMERS 66
7.2.4 DEOXYNUCLEOTIDE TRIPHOSPHATES (DNTPS) 66
7.2.5 PCR BUFFERS 66
7.2.5.1 TRIS-HCL 66
7.2.5.2 POTASSIUM CHLORIDE (KCL) 67
7.2.5.3 MAGNESIUM CHLORIDE 67
7.2.6 MASTER MIX OR PCR KIT 67
7.2.7 PROBES 67
7.2.8 ANTI-TAQ DNA POLYMERASE ANTIBODY 67
7.2.9 DIGITAL PCR SUPERMIXES 67
7.2.10 OTHERS 67
7.3 INSTRUMENTS 68
7.3.1 BY TYPE 68
7.3.1.1 DIGITAL PCR 69
7.3.1.1.1 DIGITAL PCR(DDPCR) 69
7.3.1.1.2 CHIP BASED DIGITAL PCR 69
7.3.1.1.3 BEAMING DIGITAL PCR 70
7.3.1.2 REAL TIME PCR 70
7.3.1.3 CONVENTIONAL PCR 70
7.3.1.4 OTHERS 70
7.3.2 BY MODALITY 70
7.3.2.1 STANDLONE 70
7.3.2.2 HANDHELD 70
7.3.2.3 PORTABLE 70
7.4 CONSUMABLES 71
7.4.1 PCR TUBES AND CAPS 71
7.4.2 PCR STRIPS 71
7.4.3 PCR WELL PLATES 71
7.4.4 STRIP TUBES 72
7.4.5 PLATE SEALS 72
7.4.6 CARTRIDGES AND GASKETS 72
7.4.7 OTHERS 72
7.5 SOFTWARE AND SERVICES 72
8 U.S. POLYMERASE CHAIN REACTION MARKET, BY METHOD 73
8.1 OVERVIEW 74
8.2 REAL-TIME PCR 77
8.3 REVERSE-TRANSCRIPTASE(RT) PCR 77
8.4 CONVENTIONAL PCR 78
8.5 MULTIPLEX PCR 78
8.6 NESTED PCR 78
8.7 HOT START PCR 79
8.8 LONG-RANGE PCR 79
8.9 ASSEMBLY PCR 79
8.10 INVERSE PCR 80
8.11 OTHERS 81
9 U.S. POLYMERASE CHAIN REACTION MARKET, BY APPLICATION 82
9.1 OVERVIEW 83
9.2 CLINICAL 86
9.2.1 ONCOLOGY TESTING 86
9.2.2 INFECTIOUS DISEASE TESTING 86
9.2.2.1 HUMAN PAPILLOMAVIRUS 87
9.2.2.2 HIV 87
9.2.2.3 HCV 87
9.2.2.4 HEPATITIS B VIRUS 87
9.2.2.5 OTHERS 87
9.2.3 TRANSPLANT DIAGNOSTICS 87
9.2.4 PATERNITY TESTING 87
9.2.5 OTHERS 87
9.3 LIFE SCIENCE AND RELATED RESEARCHES 88
9.3.1 MICROBIOLOGY 88
9.3.2 MOLECULAR AND CELL BIOLOGY 88
9.3.3 OTHERS 88
9.4 FORENSIC SCIENCE 89
9.4.1 DNA TYPING 89
9.4.2 DNA TESTING 89
9.4.3 GENETIC FINGERPRINTING 89
9.5 ENVIRONMENTAL MICROBIOLOGY 90
9.5.1 DETECTION OF TARGETED MICROORGANISMS 91
9.5.2 QUANTIFICATION OF MICROBIAL POPULATION 91
9.5.3 MICROBIAL COMMUNITY ANALYSIS 91
9.5.4 DETECTION OF MICROBIAL PATHOGEN 91
9.5.5 DETECTION OF GENE EXPRESSION IN THE ENVIRONMENT 91
9.5.6 DETECTION OF INDICTOR MICROORGANISMS IN WATER 91
9.5.7 ENVIRONMENTAL DNA ANALYSIS 91
9.5.8 OTHERS 91
9.6 OTHERS 92
10 U.S. POLYMERASE CHAIN REACTION MARKET, BY END USER 93
10.1 OVERVIEW 94
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 97
10.3 HOSPITALS AND CLINICS 97
10.3.1 PRIVATE 98
10.3.1.1 TIER 1 98
10.3.1.2 TIER 2 98
10.3.1.3 TIER 3 98
10.3.2 PUBLIC 98
10.3.2.1 TIER 1 99
10.3.2.2 TIER 2 99
10.3.2.3 TIER 3 99
10.4 DIAGNOSTIC LABORATORIES 99
10.5 ACADEMIC AND RESEARCH ORGANIZATIONS 99
10.6 FORENSIC LABORATORIES 100
10.7 REFERENCE LABORATORIES 100
10.8 OTHERS 100
11 U.S. POLYMERASE CHAIN REACTION MARKET, BY DISTRIBUTION CHANNEL 101
11.1 OVERVIEW 102
11.2 DIRECT TENDER 105
11.3 RETAIL SALES 105
11.4 OTHERS 106 
12 U.S. POLYMERASE CHAIN REACTION MARKET: COMPANY LANDSCAPE 107
12.1 COMPANY SHARE ANALYSIS: U.S. 107
13 SWOT ANALYSIS 108
14 U.S. POLYMERASE CHAIN REACTION MARKET, COMPANY PROFILE 109
14.1 MERCK KGAA 109
14.1.1 COMPANY SNAPSHOT 109
14.1.2 REVENUE ANALYSIS 109
14.1.3 PRODUCT PORTFOLIO 110
14.1.4 RECENT DEVELOPMENTS 110
14.2 F. HOFFMANN- LA ROCHE LTD 111
14.2.1 COMPANY SNAPSHOT 111
14.2.2 REVENUE ANALYSIS 111
14.2.3 PRODUCT PORTFOLIO 112
14.2.4 RECENT DEVELOPMENT 112
14.3 BIO-RAD LABORATORIES, INC 113
14.3.1 COMPANY SNAPSHOT 113
14.3.2 REVENUE ANALYSIS 113
14.3.3 PRODUCT PORTFOLIO 114
14.3.4 RECENT DEVELOPMENTS 114
14.4 QIAGEN 115
14.4.1 COMPANY SNAPSHOT 115
14.4.2 REVENUE ANALYSIS 115
14.4.3 PRODUCT PORTFOLIO 116
14.4.4 RECENT DEVELOPMENTS 117
14.5 AGILENT TECHNOLOGIES, INC. 118
14.5.1 COMPANY PROFILE 118
14.5.2 REVENUE ANALYSIS 118
14.5.3 PRODUCT PORTFOLIO 119
14.5.4 RECENT DEVELOPMENT 119
14.6 ABBOTT 120
14.6.1 COMPANY SNAPSHOT 120
14.6.2 REVENUE ANALYSIS 120
14.6.3 PRODUCT PORTFOLIO 121
14.6.4 RECENT DEVELOPMENT 121
14.7 BECKMAN COULTER, INC. 122
14.7.1 COMPANY SNAPSHOT 122
14.7.2 PRODUCT PORTFOLIO 122
14.7.3 RECENT DEVELOPMENTS 122
14.8 BIOMERIUX 123
14.8.1 COMPANY PROFILE 123
14.8.2 REVENUE ANALYSIS 123
14.8.4 RECENT DEVELOPMENT 124
14.9 ENZO LIFE SCIENCES, INC. 125
14.9.1 COMPANY SNAPSHOT 125
14.9.2 PRODUCT PORTFOLIO 125
14.9.3 RECENT DEVELOPMENT 125
14.10 GENSCRIPT 126
14.10.1 COMPANY SNAPSHOT 126
14.10.2 REVENUE ANALYSIS 126
14.10.3 PRODUCT PORTFOLIO 127
14.10.4 RECENT DEVELOPMENTS 127
14.11 ILLUMINA INC 128
14.11.1 COMPANY SNAPSHOT 128
14.11.2 REVENUE ANALYSIS 128
14.11.3 PRODUCT PORTFOLIO 129
14.11.4 RECENT DEVELOPMENT 129
14.12 LGC BIOSEARCH TECHNOLOGIES 130
14.12.1 COMPANY SNAPSHOT 130
14.12.2 PRODUCT PORTFOLIO 130
14.12.3 RECENT DEVELOPMENT 130
14.13 LUMINEX CORPORATION 131
14.13.1 COMPANY SNAPSHOT 131
14.13.2 PRODUCT PORTFOLIO 131
14.13.3 RECENT DEVELOPMENT 131
14.14 MERIDIAN BIOSCIENCE INC 132
14.14.1 COMPANY PROFILE 132
14.14.2 REVENUE ANALYSIS 132
14.14.4 RECENT DEVELOPMENT 133
14.15 PERKINELMER INC 134
14.15.1 COMPANY PROFILE 134
14.15.2 REVENUE ANALYSIS 134
14.15.4 RECENT DEVELOPMENT 135
14.16 PROMEGA CORPORATION 136
14.16.1 COMPANY SNAPSHOT 136
14.16.2 PRODUCT PORTFOLIO 136